CCR4 and Hodgkins lymphoma: MYO1G is abundant in T and B lymphocytes and mast cells [56], and CCR4 is a novel-specific molecular target for immunotherapy in Hodgkin lymphoma, able to regulate the cell trafficking of various leukocyte types [57].